Tenax Non Current Assets Total vs Common Stock Analysis
| TENX Stock | USD 3.55 0.04 1.11% |
Tenax Therapeutics financial indicator trend analysis is much more than just breaking down Tenax Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tenax Therapeutics is a good investment. Please check the relationship between Tenax Therapeutics Non Current Assets Total and its Common Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.
Non Current Assets Total vs Common Stock
Non Current Assets Total vs Common Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tenax Therapeutics Non Current Assets Total account and Common Stock. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Tenax Therapeutics' Non Current Assets Total and Common Stock is -0.12. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Common Stock in the same time period over historical financial statements of Tenax Therapeutics, assuming nothing else is changed. The correlation between historical values of Tenax Therapeutics' Non Current Assets Total and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Tenax Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Non Current Assets Total i.e., Tenax Therapeutics' Non Current Assets Total and Common Stock go up and down completely randomly.
Correlation Coefficient | -0.12 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Common Stock
Most indicators from Tenax Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 32.7M | 11.1M | 8.2M | 8.4M | Depreciation And Amortization | 363.8K | 122.5K | 7.6K | 7.2K |
Tenax Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Tenax Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tenax Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 6.4M | 6.9M | 6.0M | 3.4M | 11.7M | 15.5M | |
| Other Current Liab | 760.0K | 1.2M | 597.1K | 655.7K | 1.0M | 790.7K | |
| Total Current Liabilities | 2.5M | 2.1M | 1.6M | 1.8M | 3.6M | 3.8M | |
| Total Stockholder Equity | 3.8M | 4.6M | 4.2M | 1.5M | 8.1M | 12.7M | |
| Property Plant And Equipment Net | 8.5K | 176.0K | 64.8K | 294.8K | 186.7K | 0.0 | |
| Net Debt | (4.7M) | (5.9M) | (5.3M) | (1.3M) | (9.3M) | (9.8M) | |
| Retained Earnings | (236.2M) | (246.0M) | (278.5M) | (289.5M) | (297.3M) | (282.4M) | |
| Accounts Payable | 1.7M | 757.9K | 859.6K | 448.4K | 2.1M | 2.2M | |
| Cash | 4.9M | 6.3M | 5.6M | 2.1M | 9.8M | 9.6M | |
| Non Current Assets Total | 184.4K | 73.2K | 303.2K | 196.2K | 1.1K | 1.1K | |
| Cash And Short Term Investments | 5.4M | 6.7M | 5.6M | 2.1M | 9.8M | 10.0M | |
| Common Stock Shares Outstanding | 3.9K | 6.5K | 12.9K | 18.4K | 248.4K | 260.9K | |
| Liabilities And Stockholders Equity | 6.4M | 6.9M | 6.0M | 3.4M | 11.7M | 15.5M | |
| Non Current Liabilities Total | 749.8K | 60.4K | 124.2K | 183.6K | 64.2K | 0.0 | |
| Other Current Assets | 781.0K | 82.6K | 105.1K | 345.9K | 1.9M | 2.0M | |
| Other Stockholder Equity | 239.9M | 250.6M | 282.7M | 291.0M | 305.4M | 320.6M | |
| Total Liab | 2.6M | 2.2M | 1.7M | 1.9M | 3.6M | 2.8M | |
| Total Current Assets | 6.2M | 6.8M | 5.7M | 3.2M | 11.7M | 10.5M | |
| Common Stock | 674.0 | 1.3K | 2.5K | 4.6K | 30.0 | 28.5 | |
| Common Stock Total Equity | 141.0 | 379.0 | 674.0 | 1.3K | 1.1K | 1.1K | |
| Property Plant And Equipment Gross | 8.5K | 176.0K | 6.0K | 294.8K | 186.7K | 0.0 | |
| Accumulated Other Comprehensive Income | (16.2K) | 516.0 | 458.0 | (70.0) | (63.0) | (66.15) | |
| Property Plant Equipment | 8.5K | 6.6K | 64.8K | 294.8K | 265.3K | 172.3K | |
| Net Tangible Assets | 11.8M | 3.8M | 4.6M | 4.2M | 3.8M | 3.6M | |
| Retained Earnings Total Equity | (213.5M) | (227.8M) | (236.2M) | (246.0M) | (221.4M) | (232.5M) | |
| Capital Surpluse | 222.4M | 239.6M | 239.9M | 250.6M | 288.2M | 226.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Tenax Stock analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |
Is Tenax Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenax Therapeutics. If investors know Tenax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenax Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (31.04) | Return On Assets (0.68) | Return On Equity (1.61) |
The market value of Tenax Therapeutics is measured differently than its book value, which is the value of Tenax that is recorded on the company's balance sheet. Investors also form their own opinion of Tenax Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenax Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenax Therapeutics' market value can be influenced by many factors that don't directly affect Tenax Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenax Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenax Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenax Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.